{"id":"astrazeneca-fiocruz","safety":{"commonSideEffects":[{"rate":"~50","effect":"Injection site pain"},{"rate":"~40","effect":"Fatigue"},{"rate":"~35","effect":"Headache"},{"rate":"~25","effect":"Myalgia"},{"rate":"~15","effect":"Fever"},{"rate":"~10","effect":"Chills"}]},"_chembl":{"chemblId":"CHEMBL492","moleculeType":"Small molecule","molecularWeight":"276.42"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine delivers genetic instructions for the SARS-CoV-2 spike protein via a modified adenovirus vector that cannot replicate in human cells. This triggers both cellular and humoral immune responses, generating T-cell and antibody-mediated immunity against the spike protein. The approach allows rapid production and distribution while maintaining a strong safety profile.","oneSentence":"This is the AstraZeneca/Fiocruz COVID-19 vaccine (ChAdOx1 nCoV-19, Covishield), which uses a replication-deficient chimpanzee adenovirus vector carrying the SARS-CoV-2 spike protein gene to induce immune responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:02:44.932Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 prevention in adults and adolescents"}]},"trialDetails":[{"nctId":"NCT05157178","phase":"PHASE4","title":"Immunogenicity Study of the Covid-19 (Recombinante) Vaccine With a 4 or 8 Week Interval Between the First Doses.","status":"UNKNOWN","sponsor":"The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)","startDate":"2021-07-20","conditions":"COVID-19","enrollment":1264},{"nctId":"NCT05812586","phase":"PHASE3","title":"Assessment of Immunogenicity, Safety and Reactogenicity of a Booster Dose of Various COVID-19 Vaccine Platforms in Individuals Primed With Several Regimes.","status":"UNKNOWN","sponsor":"D'Or Institute for Research and Education","startDate":"2023-03-14","conditions":"COVID-19","enrollment":760},{"nctId":"NCT05470803","phase":"PHASE3","title":"An Observer-blind, Cohort Randomized, Exploratory Phase 3 Study to Evaluate the Safety and Immunogenicity of Recombinant Covid-19 Vaccine, mRNA Covid-19 Vaccine and Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine as 4th Dose in Individuals Primed/ Boosted With Various Regimens","status":"UNKNOWN","sponsor":"D'Or Institute for Research and Education","startDate":"2022-08","conditions":"COVID-19","enrollment":360},{"nctId":"NCT05087368","phase":"PHASE2","title":"Immunogenicity and Safety of Heterologous and Homologous Boosting With ChAdOx1-S and CoronaVac or a Formulation of SCB-2019 (COVID-19)","status":"UNKNOWN","sponsor":"D'Or Institute for Research and Education","startDate":"2021-12-01","conditions":"Covid19","enrollment":520}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"AstraZeneca/Fiocruz","genericName":"AstraZeneca/Fiocruz","companyName":"D'Or Institute for Research and Education","companyId":"d-or-institute-for-research-and-education","modality":"Biologic","firstApprovalDate":"","aiSummary":"AstraZeneca/Fiocruz is conducting an immunogenicity study of their Covid-19 (recombinante) vaccine with varying intervals between doses. The vaccine is a glucagon-like peptide 1 receptor agonist, a type of protein-based drug.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}